Oslo, Norway, May 15, 2026 - Lytix Biopharma ASA ("Lytix" or the "Company") will
release its first quarter 2026 financial results on Thursday, May 21th, 2026.

Join us for a live webcast presentation featuring CEO Øystein Rekdal, CFO Gjest
Breistein and CMO Karim Benhadji  where they will discuss the results and
provide key insights. 

Date: Thursday, May 21th, 2026
Time: 14:00 CET

Q&A Session:
We welcome your questions in advance. Please send them to
post@lytixbiopharma.com, and they will be addressed during the Q&A session
following the presentation.

Webcast Details:
The presentation and Q&A session will be conducted in English. You can view the
live event by registering here: https://qcnl.tv/p/s6roJjTDW6gVSNwfqof5Rw 

Missed the Live Session?
A recording of the presentation will be available shortly after the event on our
financial reports page: https://www.lytixbiopharma.com/financial-reports  

For more information, please contact: 
Gjest Breistein, CFO 
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma's lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.
For more information, visit www.lytixbiopharma.com.
	

For more information\, visit www.lytixbiopharma.com.\
	\